Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels.
Acetylcholine
/ metabolism
Alzheimer Disease
/ drug therapy
Animals
Calcium Channels, T-Type
/ physiology
Calcium-Calmodulin-Dependent Protein Kinase Type 2
/ metabolism
Hippocampus
/ physiology
Humans
Imidazoles
/ pharmacology
Neurogenesis
Proteasome Endopeptidase Complex
/ metabolism
Spiro Compounds
/ pharmacology
Alzheimer's disease
CaMKII
Cognitive function
Proteasome activity
T-type Ca(2+) channel enhancer
Journal
Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
03
04
2018
revised:
16
11
2018
accepted:
20
11
2018
pubmed:
3
1
2019
medline:
18
4
2019
entrez:
3
1
2019
Statut:
ppublish
Résumé
Low-threshold Ca
Identifiants
pubmed: 30600144
pii: S1347-8613(18)30224-X
doi: 10.1016/j.jphs.2018.11.014
pii:
doi:
Substances chimiques
Calcium Channels, T-Type
0
Imidazoles
0
SAK3 compound
0
Spiro Compounds
0
Calcium-Calmodulin-Dependent Protein Kinase Type 2
EC 2.7.11.17
Proteasome Endopeptidase Complex
EC 3.4.25.1
Acetylcholine
N9YNS0M02X
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-58Informations de copyright
Copyright © 2018 The Authors. Production and hosting by Elsevier B.V. All rights reserved.